Recovery
Larazotide
Also called AT-1001, INN-202
per administration
A human trial worked out how much to take and how often, so a dosing schedule is shown.
The human evidence for Larazotide used the oral route. The draw worked out here assumes a subcutaneous injection, so the amount is not a direct read-across.
Work out your draw
These numbers are a starting point — change any of them.
- Concentration
- 0.33mg/mL
- Volume per draw
- 1.5mL
- Units to dial
- 150
- Doses per cartridge
- 2
This is 150 units, past the 60-unit dial. Splitting it across administrations, or using less water to raise the concentration, brings it back into range.
Dial range varies by pen; 1–60 units is the common configuration.
Vial label
Copy this into your label printer.
Published research contexts for Larazotide describe 0.5–2 mg per administration. Descriptive only, not a recommendation.
Acts locally in the gut with minimal systemic absorption, so a plasma half-life is not the relevant figure.
Taken by mouth and minimally absorbed, acting locally in the gut, so a subcutaneous draw does not apply and no schedule table is shown. The human evidence is oral (0.5–2 mg three times daily); the vial size shown is nominal.
Where these numbers come from
- Leffler DA et al., Gastroenterology 2015;148:1311Oral larazotide acetate at 0.5, 1 and 2 mg three times daily assessed in celiac disease; the 0.5 mg amount was carried forward.